Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksLNAI +4.40%13 3-1 Month Momentum % is -42.72% as of Sep. 22, 2026. GuruFocus rates LNAI with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 1,383 Biotechnology companies, Lunai Bioworks ranks worse than 94.14% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Lunai Bioworks's 3-1 Month Momentum % is -42.72%.
The industry rank for Lunai Bioworks's 3-1 Month Momentum % or its related term are showing as below:
LNAI's 3-1 Month Momentum % is ranked worse than 94.14% of 1383
companies
in the Biotechnology industry
Industry Median: 0.47
vs LNAI: -42.72
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Lunai Bioworks 3-1 Month Momentum % Related Terms
LNAI vs AZTR, GDTC, APRE: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Lunai Bioworks's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lunai Bioworks (LNAI) has a 3-1 Month Momentum % of -42.72% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #1302 out of 1383 companies in the Biotechnology industry, placing it in the top 94.1%.
Is Lunai Bioworks' 3-1 Month Momentum % too high?
Lunai Bioworks' current 3-1 Month Momentum % is -42.72%. Based on the distribution chart, Lunai Bioworks ranks #1302 out of 1383 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' 3-1 Month Momentum % compare to AZTR and GDTC?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #1302 out of 1383 companies for 3-1 Month Momentum %. This places Lunai Bioworks in the lower half of its industry. The industry median 3-1 Month Momentum % is 0.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.47, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current 3-1 Month Momentum % is -42.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (LNAI) has a current 3-1 Month Momentum % of -42.72%. The current 3-1 Month Momentum % is -42.72%. Lunai Bioworks' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Lunai Bioworks (LNAI), the current 3-1 Month Momentum % is -42.72% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
13GF Score
Get the complete analysis for LNAI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNAI has been successfully added to your 
